Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
1.0 |
High Similarity |
NPD220 |
Clinical (unspecified phase) |
1.0 |
High Similarity |
NPD218 |
Approved |
1.0 |
High Similarity |
NPD219 |
Phase 3 |
1.0 |
High Similarity |
NPD216 |
Approved |
1.0 |
High Similarity |
NPD217 |
Approved |
0.979 |
High Similarity |
NPD214 |
Approved |
0.979 |
High Similarity |
NPD213 |
Clinical (unspecified phase) |
0.9533 |
High Similarity |
NPD247 |
Clinical (unspecified phase) |
0.8966 |
High Similarity |
NPD250 |
Approved |
0.8966 |
High Similarity |
NPD249 |
Approved |
0.8844 |
High Similarity |
NPD195 |
Approved |
0.8844 |
High Similarity |
NPD186 |
Discovery |
0.8609 |
High Similarity |
NPD283 |
Approved |
0.8571 |
High Similarity |
NPD185 |
Approved |
0.8497 |
Intermediate Similarity |
NPD242 |
Approved |
0.8497 |
Intermediate Similarity |
NPD1750 |
Clinical (unspecified phase) |
0.8497 |
Intermediate Similarity |
NPD338 |
Approved |
0.8497 |
Intermediate Similarity |
NPD3107 |
Discontinued |
0.8497 |
Intermediate Similarity |
NPD1369 |
Phase 2 |
0.8456 |
Intermediate Similarity |
NPD166 |
Approved |
0.8452 |
Intermediate Similarity |
NPD2624 |
Phase 2 |
0.8442 |
Intermediate Similarity |
NPD339 |
Approved |
0.8435 |
Intermediate Similarity |
NPD193 |
Suspended |
0.8387 |
Intermediate Similarity |
NPD169 |
Phase 2 |
0.8333 |
Intermediate Similarity |
NPD1732 |
Phase 3 |
0.8333 |
Intermediate Similarity |
NPD2646 |
Discontinued |
0.8117 |
Intermediate Similarity |
NPD548 |
Clinical (unspecified phase) |
0.8081 |
Intermediate Similarity |
NPD4054 |
Clinical (unspecified phase) |
0.8069 |
Intermediate Similarity |
NPD9632 |
Phase 3 |
0.7927 |
Intermediate Similarity |
NPD2647 |
Phase 3 |
0.7919 |
Intermediate Similarity |
NPD252 |
Clinical (unspecified phase) |
0.7847 |
Intermediate Similarity |
NPD9084 |
Phase 2 |
0.7806 |
Intermediate Similarity |
NPD1730 |
Discontinued |
0.7798 |
Intermediate Similarity |
NPD5666 |
Phase 2 |
0.7719 |
Intermediate Similarity |
NPD4716 |
Approved |
0.7703 |
Intermediate Similarity |
NPD248 |
Discontinued |
0.7688 |
Intermediate Similarity |
NPD1692 |
Approved |
0.7683 |
Intermediate Similarity |
NPD3083 |
Approved |
0.7674 |
Intermediate Similarity |
NPD4744 |
Clinical (unspecified phase) |
0.7654 |
Intermediate Similarity |
NPD546 |
Clinical (unspecified phase) |
0.7651 |
Intermediate Similarity |
NPD7988 |
Suspended |
0.7647 |
Intermediate Similarity |
NPD4171 |
Clinical (unspecified phase) |
0.7616 |
Intermediate Similarity |
NPD194 |
Clinical (unspecified phase) |
0.7602 |
Intermediate Similarity |
NPD1412 |
Clinical (unspecified phase) |
0.7597 |
Intermediate Similarity |
NPD549 |
Approved |
0.7545 |
Intermediate Similarity |
NPD1777 |
Approved |
0.7545 |
Intermediate Similarity |
NPD1776 |
Approved |
0.7516 |
Intermediate Similarity |
NPD9605 |
Phase 3 |
0.7515 |
Intermediate Similarity |
NPD516 |
Clinical (unspecified phase) |
0.745 |
Intermediate Similarity |
NPD870 |
Clinical (unspecified phase) |
0.7401 |
Intermediate Similarity |
NPD5683 |
Clinical (unspecified phase) |
0.7401 |
Intermediate Similarity |
NPD5682 |
Phase 3 |
0.7401 |
Intermediate Similarity |
NPD5684 |
Clinical (unspecified phase) |
0.7401 |
Intermediate Similarity |
NPD6417 |
Clinical (unspecified phase) |
0.7389 |
Intermediate Similarity |
NPD582 |
Approved |
0.7351 |
Intermediate Similarity |
NPD8829 |
Clinical (unspecified phase) |
0.732 |
Intermediate Similarity |
NPD9083 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD2632 |
Approved |
0.7222 |
Intermediate Similarity |
NPD2631 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD2630 |
Approved |
0.7186 |
Intermediate Similarity |
NPD4074 |
Clinical (unspecified phase) |
0.7134 |
Intermediate Similarity |
NPD3086 |
Phase 3 |
0.7091 |
Intermediate Similarity |
NPD536 |
Clinical (unspecified phase) |
0.7073 |
Intermediate Similarity |
NPD3085 |
Phase 1 |
0.7072 |
Intermediate Similarity |
NPD7138 |
Phase 2 |
0.7059 |
Intermediate Similarity |
NPD9633 |
Phase 3 |
0.6975 |
Remote Similarity |
NPD7158 |
Phase 1 |
0.6974 |
Remote Similarity |
NPD9408 |
Phase 3 |
0.6913 |
Remote Similarity |
NPD9607 |
Approved |
0.6887 |
Remote Similarity |
NPD8830 |
Phase 3 |
0.6867 |
Remote Similarity |
NPD3708 |
Phase 2 |
0.6846 |
Remote Similarity |
NPD9606 |
Approved |
0.6772 |
Remote Similarity |
NPD209 |
Clinical (unspecified phase) |
0.6753 |
Remote Similarity |
NPD2877 |
Clinical (unspecified phase) |
0.6753 |
Remote Similarity |
NPD2876 |
Phase 3 |
0.6709 |
Remote Similarity |
NPD545 |
Clinical (unspecified phase) |
0.6701 |
Remote Similarity |
NPD2965 |
Clinical (unspecified phase) |
0.6686 |
Remote Similarity |
NPD231 |
Clinical (unspecified phase) |
0.6684 |
Remote Similarity |
NPD2824 |
Phase 2 |
0.6644 |
Remote Similarity |
NPD9374 |
Approved |
0.6627 |
Remote Similarity |
NPD353 |
Discontinued |
0.6604 |
Remote Similarity |
NPD547 |
Clinical (unspecified phase) |
0.6579 |
Remote Similarity |
NPD307 |
Approved |
0.6548 |
Remote Similarity |
NPD796 |
Phase 2 |
0.6524 |
Remote Similarity |
NPD3695 |
Approved |
0.6524 |
Remote Similarity |
NPD3696 |
Approved |
0.651 |
Remote Similarity |
NPD9373 |
Approved |
0.6503 |
Remote Similarity |
NPD1046 |
Clinical (unspecified phase) |
0.6468 |
Remote Similarity |
NPD2902 |
Phase 2 |
0.6468 |
Remote Similarity |
NPD2903 |
Clinical (unspecified phase) |
0.6467 |
Remote Similarity |
NPD171 |
Discontinued |
0.645 |
Remote Similarity |
NPD775 |
Approved |
0.6439 |
Remote Similarity |
NPD534 |
Phase 2 |
0.6439 |
Remote Similarity |
NPD537 |
Phase 2 |
0.6402 |
Remote Similarity |
NPD2152 |
Clinical (unspecified phase) |
0.6392 |
Remote Similarity |
NPD9366 |
Approved |
0.6386 |
Remote Similarity |
NPD1431 |
Approved |
0.6386 |
Remote Similarity |
NPD1430 |
Approved |
0.6368 |
Remote Similarity |
NPD4495 |
Phase 1 |
0.6335 |
Remote Similarity |
NPD282 |
Approved |
0.6319 |
Remote Similarity |
NPD1119 |
Phase 2 |
0.6296 |
Remote Similarity |
NPD1063 |
Phase 2 |
0.6259 |
Remote Similarity |
NPD9626 |
Clinical (unspecified phase) |
0.6257 |
Remote Similarity |
NPD527 |
Clinical (unspecified phase) |
0.6218 |
Remote Similarity |
NPD9409 |
Discontinued |
0.6213 |
Remote Similarity |
NPD4240 |
Approved |
0.6205 |
Remote Similarity |
NPD1808 |
Phase 1 |
0.619 |
Remote Similarity |
NPD2253 |
Discontinued |
0.6184 |
Remote Similarity |
NPD5080 |
Phase 2 |
0.6135 |
Remote Similarity |
NPD5079 |
Phase 2 |
0.6118 |
Remote Similarity |
NPD9375 |
Discontinued |
0.6108 |
Remote Similarity |
NPD4089 |
Clinical (unspecified phase) |
0.6084 |
Remote Similarity |
NPD1120 |
Approved |
0.6084 |
Remote Similarity |
NPD1121 |
Approved |
0.6049 |
Remote Similarity |
NPD1127 |
Approved |
0.6049 |
Remote Similarity |
NPD1128 |
Approved |
0.6025 |
Remote Similarity |
NPD281 |
Approved |
0.5988 |
Remote Similarity |
NPD515 |
Phase 1 |
0.5982 |
Remote Similarity |
NPD6840 |
Approved |
0.5979 |
Remote Similarity |
NPD207 |
Discontinued |
0.597 |
Remote Similarity |
NPD4458 |
Phase 2 |
0.597 |
Remote Similarity |
NPD4459 |
Clinical (unspecified phase) |
0.5964 |
Remote Similarity |
NPD1058 |
Discontinued |
0.5952 |
Remote Similarity |
NPD6112 |
Approved |
0.5952 |
Remote Similarity |
NPD9551 |
Approved |
0.5952 |
Remote Similarity |
NPD9550 |
Approved |
0.592 |
Remote Similarity |
NPD7531 |
Clinical (unspecified phase) |
0.5897 |
Remote Similarity |
NPD9584 |
Phase 2 |
0.5894 |
Remote Similarity |
NPD9291 |
Approved |
0.5893 |
Remote Similarity |
NPD535 |
Approved |
0.5876 |
Remote Similarity |
NPD7842 |
Phase 2 |
0.5828 |
Remote Similarity |
NPD8836 |
Approved |
0.5824 |
Remote Similarity |
NPD799 |
Phase 1 |
0.5794 |
Remote Similarity |
NPD245 |
Suspended |
0.5786 |
Remote Similarity |
NPD9360 |
Approved |
0.5771 |
Remote Similarity |
NPD691 |
Discontinued |
0.5756 |
Remote Similarity |
NPD1118 |
Discontinued |
0.574 |
Remote Similarity |
NPD4654 |
Phase 1 |
0.5734 |
Remote Similarity |
NPD1273 |
Discontinued |
0.5721 |
Remote Similarity |
NPD8250 |
Phase 2 |
0.5714 |
Remote Similarity |
NPD9417 |
Phase 3 |
0.5714 |
Remote Similarity |
NPD9416 |
Phase 3 |
0.5707 |
Remote Similarity |
NPD5486 |
Discontinued |
0.5706 |
Remote Similarity |
NPD798 |
Discontinued |
0.5696 |
Remote Similarity |
NPD757 |
Phase 3 |
0.5695 |
Remote Similarity |
NPD7502 |
Clinical (unspecified phase) |
0.5687 |
Remote Similarity |
NPD237 |
Clinical (unspecified phase) |
0.5676 |
Remote Similarity |
NPD2593 |
Clinical (unspecified phase) |
0.5676 |
Remote Similarity |
NPD1572 |
Phase 2 |
0.5671 |
Remote Similarity |
NPD78 |
Approved |
0.5671 |
Remote Similarity |
NPD9544 |
Approved |
0.5647 |
Remote Similarity |
NPD9484 |
Clinical (unspecified phase) |
0.5629 |
Remote Similarity |
NPD9571 |
Approved |
0.5625 |
Remote Similarity |
NPD5458 |
Discontinued |
0.5625 |
Remote Similarity |
NPD6023 |
Discontinued |
0.5622 |
Remote Similarity |
NPD6381 |
Phase 2 |
0.5604 |
Remote Similarity |
NPD4714 |
Approved |
0.5604 |
Remote Similarity |
NPD34 |
Approved |
0.5604 |
Remote Similarity |
NPD4713 |
Clinical (unspecified phase) |
0.5604 |
Remote Similarity |
NPD4715 |
Clinical (unspecified phase) |
0.56
|
Remote Similarity |
NPD1117 |
Clinical (unspecified phase) |